Hong Kong Regulators Review Manufacturing, Supply Chain Regulations In Wake Of Tainted Products Leading To Six Deaths
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - A review of Hong Kong's drug regulatory infrastructure could lead to more stringent requirements for pharmaceutical manufacturers, importers and distributors